Avibactam confers susceptibility to a large proportion of ceftazidimeresistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1596-1598

  Chalhoub, Hussein ^a   Tunney, Michael ^b   Stuart Elborn, J ^b   Vergison, Anne ^c   Denis, Olivier ^d   Plésiat, Patrick ^e   Kahl, Barbara C ^f   Van Bambeke, Françoise ^a   Tulkens, Paul M ^a,g  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g Union Nationale des Mutualités Socialistes   (Belgium)

Author keywords

Carbapenemases; Esbls; Extended spectrum lactamases; P. aeruginosa; lactamase inhibition

Indexed keywords

AVIBACTAM; CEFTAZIDIME; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR;

BACTERIUM ISOLATION; CYSTIC FIBROSIS; DRUG SENSITIVITY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; ANTIBIOTIC RESISTANCE; COMPLICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; CYSTIC FIBROSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84929761996     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku551     Document Type: Letter

References (9)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry-2012 Annual Data Report. http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf.
2. Llanes C, Pourcel C, Richardot C et al. Diversity of b-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J Antimicrob Chemother 2013; 68: 1763-71.
3. Gaspar MC, Couet W, Olivier JC et al. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis 2013; 32: 1231-52.
4. Young DC, Zobell JT, Stockmann C et al. Optimization of antipseudomonal antibiotics for cystic fibrosis pulmonary exacerbations:V. Aminoglycosides. Pediatr Pulmonol 2013; 48: 1047-61.
5. Conway SP, Pond MN, Watson A et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997; 52: 987-93.
6. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against class A, C, and D b-lactamases. J Biol Chem 2013; 288: 27960-71.
7. Walkty A, DeCorby M, Lagace-Wiens PRS et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother 2011; 55: 2992-4.
8. Flamm RK, Stone GG, Sader HS et al. Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother 2014; 26: 333-8.
9. Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+ NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010; 65: 2376-81.